FilingReader Intelligence
Huadong Medicine subsidiary gets clinical trial approval for cancer drug
July 18, 2025 at 08:10 AM UTC•By FilingReader AI
Huadong Medicine's subsidiary received clinical trial approval from China's NMPA for HDM2012, an antibody-drug conjugate targeting advanced solid tumors.
The application was fast-tracked under a pilot program, significantly shortening the review period for the Class 1 therapeutic biological product.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SZSE:000963•Shenzhen Stock Exchange
News Alerts
Get instant email alerts when Huadong Medicine publishes news
Free account required • Unsubscribe anytime